Founded in December 2017,We are a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent therapeutic candidates to treat cancer and Nephropathy.
BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China
BioCity Announces Initiation of a Phase 2 Trial for SC0062, a Promising ETA Receptor Antagonist for Chronic Kidney Disease
WUXI, China, June 21, 2023 /PRNewswire/ -- BioCity Biopharma, a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent therapeutics for cancer and autoimmune disorders, today announced the initiation of a randomized, placebo-controlled Phase 2 clinical trial of its novel, oral endothelin A (ETA)-receptor selective antagonist, SC0062, with the enrollment of two patients with IgA nephropathy(IgAN)in China(NCT05687890).
We have always been adhering to the mission of "Better Medicine for Better Life", and dedicate to developing "BIC/FIC" drugs with unmet needs.
We invite like-minded you to join us to create a healing tomorrow together.